Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia

ClinicalTrials.gov ID: NCT07936201

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07936201. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Multi-Institutional Study of Combination of Luspatercept With Pacritinib (LusPACercept) in Patients With Myelofibrosis Associated Anemia and Thrombocytopenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is for participants who have been diagnosed with myelofibrosis with cytopenia. Luspatercept and Pacritinib are experimental drug combination that works by blocking certain enzymes to calm an overactive inmmune system to reduce inflammation which would allow red blood cells to mature. The purpose of this study is to find out if the combination of Luspatercept and Pacritinib can help improve hemobglobin or transfusion dependents in participants with myelofibrosis with cytopenias.

Study identification

NCT ID: NCT07936201
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Case Comprehensive Cancer Center; Other
Enrollment: 50 participants

Conditions and interventions

Conditions

Myelofibrosis

Interventions

Luspatercept Drug
Pacritinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2026 (Estimated)
Primary completion: Jan 1, 2029 (Estimated)
Completion: Jan 1, 2029 (Estimated)
Last update posted: Nov 13, 2026

2026 – 2029

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Cleveland Clinic Foundation	Cleveland	Ohio	44196	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07936201, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 13, 2026 · Synced Nov 15, 2026